skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer

Review

(1775) Views  (501) Full article downloads

Authors: Daiki Ogawara, Minoru Fukuda, Yoichi Nakamura, et al

Published Date August 2010 Volume 2010:2 Pages 191 - 195
DOI: http://dx.doi.org/10.2147/CMAR.S7777

Daiki Ogawara1, Minoru Fukuda2, Yoichi Nakamura3, Shigeru Kohno3
1Department of Medicine, Sasebo Central Hospital, 2Department of Medicine, Nagasaki Municipal Hospital, 3Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan

Abstract: Long-term survival is quite uncommon in refractory small cell lung cancer (SCLC) patients, with less than 25% of patients with limited-stage disease and 1%–2% of patients with extensive-stage disease remaining alive at five years. Recent clinical studies have demonstrated the promising efficacy of amrubicin for patients with relapsed SCLC. This review presents the results of clinical studies showing the efficacy and safety of amrubicin for the treatment of relapsed SCLC. Amrubicin is a synthetic anthracycline agent with a similar structure to doxorubicin, in which the hydroxyl group at position 9 in amrubicin is replaced by an amino group to enhance efficacy. It is converted to an active metabolite, amrubicinol, which is 5–54 times more active than amrubicin. Amrubicin and amrubicinol are inhibitors of DNA topoisomerase II, exerting their cytotoxic effects by stabilizing a topoisomerase II-mediated cleavable complex. The toxicity of amrubicin is similar to that of doxorubicin, although amrubicin shows almost no cardiotoxicity. In the relevant trials, amrubicin was administered intravenously at a dose of 35–40 mg/m2 on days 1–3 every three weeks. The response rate was 34%–52% and median survival times were 8.1–12.0 months. Common hematologic toxicities included neutropenia, leucopenia, anemia, thrombocytopenia, and febrile neutropenia. Nonhematologic adverse events included Grade 3–4 anorexia, asthenia, hyponatremia, and nausea. The results of the studies which demonstrated the efficacy of monotherapy for relapsed SCLC involved mainly Japanese patients. Therefore, it is necessary to conduct more clinical studies in non-Japanese patients to confirm the efficacy of amrubicin.

Keywords: amrubicin, amrubicinol, small cell lung cancer, relapse






Readers of this article also read:

Topotecan in the treatment of relapsed small cell lung cancer
Optimal management of cancer anorexia–cachexia syndrome
Role of bevacizumab therapy in the management of glioblastoma
Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer
Circulating tumor cells (CTCs) in lung cancer: current status and future perspectives
Epigenomics in cancer management
Efficacy and safety of fentanyl buccal for cancer pain management by administration through a soluble film: an update
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics
Emerging treatment options in the management of non-small cell lung cancer
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University